MANTA1 study: Paclitaxel maintenance after first line chemotherapy with anthracyclines plus paclitaxel in metastatic breast cancer patients

被引：0

作者：

De Lena, M

Conte, PF

Manzione, L

Amadori, D

Del Mastro, L

Moretti, G

Grifalchi, F

Valsecchi, R

Fedeli, SL

Lionetto, R

Gennari, A

机构：

[1] IRCCS, Dept Oncol, Bari, Italy

[2] S Chiara Hosp, Dept Oncol, Pisa, Italy

[3] S Carlo Hosp, Dept Oncol, Potenza, Italy

[4] Pierantoni Hosp, Dept Oncol, Forli, Italy

[5] IST, Dept Oncol, Genoa, Italy

[6] Spallanzani Hosp, Dept Oncol, Reggio Emilia, Italy

[7] Univ La Sapienza, Dept Oncol, Rome, Italy

[8] S Carlo Borromeo Hosp, Dept Oncol, Milan, Italy

[9] S Salvatore Hosp, Dept Oncol, Pesaro, Italy

[10] IST, Adv Biotecnol Ctr, Genoa, Italy

来源：

ANNALS OF ONCOLOGY | 2000年 / 11卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

E23

引用

页码：40 / 40

页数：1

共 50 条

[1] Paclitaxel (P) maintenance following first line chemotherapy with anthracyclines plus paclitaxel in metastatic breast cancer (MBC): preliminary results from the MANTA 1 study.
Conte, PF
ANNALS OF ONCOLOGY, 2000, 11 : 23 - 23
[2] Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
Gennari, Alessandra
Amadori, Dino
De Lena, Mario
Nanni, Oriana
Bruzzi, Paolo
Lorusso, Vito
Manzione, Luigi
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3912 - 3918
[3] Paclitaxel/mitoxantrone as first line chemotherapy for metastatic breast cancer
Enrech, S
Rivero, B
DeGranda, JI
Tafalla, JJ
Cerezuela, P
Menendez, PC
Lopez, G
Claros, F
Brana, J
Sancho, JF
10TH MEDITERRANEAN CONGRESS OF CHEMOTHERAPY, 1996, : 485 - 488
[4] Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer
Acuña, LR
Langhi, M
Pérez, J
Acuña, JR
Machiavelli, M
Lacava, J
Vallejo, C
Romero, A
Fasce, H
Ortiz, E
Grasso, S
Amato, S
Rodríguez, R
Barbieri, M
Leone, B
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 74 - 81
[5] Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer
Delfino, C
Caccia, G
Gonzáles, LR
Mickiewicz, E
Rodger, J
Balbiani, L
Morales, DF
Comba, AZ
Brosio, C
ONCOLOGY, 2004, 66 (01) : 18 - 23
[6] Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study.
Gennari, A
Conte, P
Nanni, O
Manzione, L
Cortesi, E
Boni, C
Del Mastro, L
Bruzzi, P
Lo Russo, V
de Lena, M
Amadori, D
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 9S - 9S
[7] Multicenter randomised trial of paclitaxel maintenance chemotherapy versus control in metastatic breast cancer patients achieving a response or stable disease to first-line chemotherapy including anthraciclines and paclitaxel: final results from the italian MANTA study.
Gennari, A
Conte, P
Nanni, O
Manzione, L
Cortesi, E
Boni, C
Del Mastro, L
Bruzzi, P
Lo Russo, V
de Lena, M
Amadori, DS
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S199 - S199
[8] Weekly 1-hour paclitaxel as first line chemotherapy for advanced and metastatic breast cancer
Wist, EA
Sommer, HH
Oestenstad, B
Risberg, T
Fjaestad, K
INTERNATIONAL JOURNAL OF CANCER, 2002, : 138 - 138
[9] Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines
Martin, M
Casado, A
Segura, PP
Carbonero, IG
Diaz-Rubio, E
Lluch, A
Garcia-Conde, J
ONCOLOGY-NEW YORK, 1998, 12 (01): : 28 - 30
[10] A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
Perez, EA
Hillman, DW
Stella, PJ
Krook, JE
Hartmann, LC
Fitch, TR
Hatfield, AK
Mailliard, JA
Nair, S
Kardinal, CG
Ingle, JN
CANCER, 2000, 88 (01) : 124 - 131

← 1 2 3 4 5 →